PhRMA Urges FDA To Flesh Out Medicare Act Provisions On 180-Day Exclusivity

Law360, New York (May 7, 2004, 12:00 AM EDT) -- A trade group representing drug originators has urged the U.S. Food and Drug Administration to define key terms in the Medicare Prescription Drug Act’s patent reforms concerning 180-day marketing exclusivity.

The Pharmaceutical Research and Manufacturers of America (PhRMA) says the FDA should define the terms first applicant date certifications" and "lawfully maintained" to avoid speculative challenges of innovator patents and delayed generic drug competition.

Under the law, only generic drug applicants that meet the definition of a "first applicant" are eligible for 180-day exclusivity. That definition...
To view the full article, register now.

Law360 UK

UK Financial Services

Read Our Latest UK Legal News & Analysis

Financial Services Law360 UK and Insurance Law360 UK provide breaking news and in-depth analysis on U.K. and European Union regulation, enforcement, legislation, and litigation involving banks, investment firms, insurers, and more.